TG01, a new potent COX-2 inhibitor in combination with erlotinib in metastatic or recurrent non-small cell lung cancer (NSCLC) patients: A phase 1 study

Reckamp, Karen L.; Patel, Rishi; Chen, L.; Gitlitz, Barbara J.; Davies, Angela M.; Jezior, Deborah; Zaknoen, Sara

doi:10.1200/jco.2008.26.15_suppl.14661

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, impressive phase II data for the combination of carboplatin, pemetrexed and bevacizumab (reporting a RR of 55%) have spurned a phase III effort assessing the three-drug combination. (13, 14)…”

Section: Vegf- and Vegfr-directed Therapiesmentioning

confidence: 99%

“…Recent clinical investigations have also focused on more specific inhibitors of COX-2 with higher affinity, such as apricoxib. (150) In parallel, correlative studies have biomarkers to predict response to COX-2 inhibitors. For example, in a randomized phase II trial comparing celecoxib with or without the 5-lipoxygenase inhibitor zileuton in advanced NSCLC, survival with celecoxib was inversely proportional to the level of COX-2 expression.…”

Section: Cox-2 Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape

Pal

Figlin

Reckamp

2010

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Over the past decade, a multitude of targeted agents have been explored in the treatment of advanced non-small cell lung cancer (NSCLC). Thus far, two broad classes of agents have been implemented in clinical practice: (1) vascular endothelial growth factor (VEGF)-directed therapies and (2) antagonists of the epidermal growth factor receptor (EGFR). In the former category, the agent bevacizumab (a monoclonal antibody) has shown landmark improvements in survival when added to cytotoxic therapy. Small molecule tyrosine kinase inhibitors (TKIs) targeting the VEGF receptor (i.e., sunitinib, sorafenib, and vandetanib) show activity in phase II clinical studies. With respect to EGFR-directed therapies, the TKIs gefitinib and erlotinib have demonstrated significant benefit, and have uncovered valuable information regarding the biology of lung cancer. Outside of therapies directed specifically at VEGF- and EGFR-mediated signaling, trials evaluating insulin-like growth factor-1 receptor (IGF-IR)-targeting agents, cyclooxygenase-2 (COX-2) inhibitors, c-met inhibitors, irreversible pan-HER inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and histone deacetylase (HDAC) inhibitors are ongoing. Inhibitors of ALK show great promise in patients with the relevant gene translocation. Herein, the clinical development of novel therapies for NSCLC is described, including some discussion of relevant biomarkers and determination of synergy with both cytotoxic therapy and other targeted agents.

show abstract

Section: Vegf- and Vegfr-directed Therapiesmentioning

confidence: 99%

Section: Cox-2 Inhibitorsmentioning

confidence: 99%